These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 35675941

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts.
    Holmberg LA, Linenberger M, Connelly-Smith L.
    Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.
    Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG.
    Biol Blood Marrow Transplant; 2020 May; 26(5):876-883. PubMed ID: 31785375
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    Hartmann T, Hübel K, Monsef I, Engert A, Skoetz N.
    Cochrane Database Syst Rev; 2015 Oct 20; 2015(10):CD010615. PubMed ID: 26484982
    [Abstract] [Full Text] [Related]

  • 8. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience.
    Lee KH, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.
    Vox Sang; 2014 Nov 20; 107(4):407-15. PubMed ID: 25130876
    [Abstract] [Full Text] [Related]

  • 9. Threshold for optimal administration of plerixafor in autologous peripheral blood stem cell collections through CD34+ cell monitoring based on the experience from two Japanese university hospitals.
    Okubo M, Furuta Y, Nakamura Y, Osawa T, Tada N, Sawada T, Yamatoya K, Sekiguchi Y, Araki Y, Miyake K, Noguchi M, Komatsu N, Ohsaka A.
    Ther Apher Dial; 2021 Oct 20; 25(5):687-696. PubMed ID: 33325621
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.
    Tolomelli G, Mancuso K, Tacchetti P, Patriarca F, Galli M, Pantani L, Zannetti B, Motta MR, Rizzi S, Dan E, Sinigaglia B, Giudice V, Olmo A, Arpinati M, Chirumbolo G, Fanin R, Lewis RE, Paris L, Bonifazi F, Cavo M, Curti A, Lemoli RM.
    Bone Marrow Transplant; 2020 May 20; 55(5):946-954. PubMed ID: 31768009
    [Abstract] [Full Text] [Related]

  • 12. Third time's a charm? Mobilization of autologous peripheral blood stem cells in patients with two previous failed mobilizations with plerixafor.
    Zhuang L, Boriboonnangkul P, Wang S, Yuan S.
    Transfusion; 2020 Jun 20; 60(6):1253-1259. PubMed ID: 32483875
    [Abstract] [Full Text] [Related]

  • 13. [Efficacy and Safety of Plerixafor Combined with G-CSF for Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization in Lymphoma Patients].
    Guan FS, He DH, Li Y, Zhang Y, Zheng GF, Zhu YY, He JS, Zhang EF, Cai Z, Zhao Y.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug 20; 31(4):1056-1060. PubMed ID: 37551477
    [Abstract] [Full Text] [Related]

  • 14. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents.
    Mina R, Petrucci MT, Bonello F, Bongarzoni V, Saccardi R, Bertuglia G, Mengarelli A, Spadaro A, Lisi C, Curci P, Lemoli RM, Ballanti S, Floris R, Cupelli L, Tosi P, Olivieri A, Rota-Scalabrini D, Cangialosi C, Nozzoli C, Anaclerico B, Fazio F, Bruno B, Mancuso K, Corradini P, Milone G, Boccadoro M.
    Haematologica; 2024 May 01; 109(5):1525-1534. PubMed ID: 37981892
    [Abstract] [Full Text] [Related]

  • 15. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
    Javanbakht A, Stringer S, Anderson H, Hamilton E, Philip A, Waller EK, Langston AA, Joseph N, Roback JD, Schneider T, Sullivan HC, Hendrickson JE.
    J Clin Apher; 2024 Jun 01; 39(3):e22127. PubMed ID: 38803152
    [Abstract] [Full Text] [Related]

  • 16. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.
    Biol Blood Marrow Transplant; 2012 Oct 01; 18(10):1564-72. PubMed ID: 22683613
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK.
    Transfusion; 2011 Oct 01; 51(10):2175-82. PubMed ID: 21492180
    [Abstract] [Full Text] [Related]

  • 18. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
    He X, Jiang D, Zhao L, Chen S, Zhu Y, He Q, He Y.
    Cancer Med; 2024 Jun 01; 13(11):e7356. PubMed ID: 38850125
    [Abstract] [Full Text] [Related]

  • 19. Addition of plerixafor in poorly mobilized allogeneic stem cell donors.
    Zhuang L, Lauro D, Wang S, Yuan S.
    J Clin Apher; 2022 Aug 01; 37(4):388-394. PubMed ID: 35633513
    [Abstract] [Full Text] [Related]

  • 20. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.
    Pharmacotherapy; 2012 Jul 01; 32(7):596-603. PubMed ID: 22760691
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.